Overview

Study Evaluating the Pharmacokinetics of the Potential Drug Interaction Between HCV-796 and Desipramine

Status:
Completed

Trial end date:
2007-08-01

Target enrollment:

Participant gender:

Summary

To evaluate the potential pharmacokinetic (PK) interaction of multiple oral doses of HCV-796 and a single dose of desipramine when coadministered to healthy subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Wyeth is now a wholly owned subsidiary of Pfizer

Collaborator:

ViroPharma

Treatments:

Desipramine